A Systematic Switch From Originator Infliximab to Biosimilar Infliximab in Patients With Non-Infectious Uveitis

PurposeTo investigate the efficacy of biosimilar infliximab compared to that originator for treatment chronic non-infectious uveitis.DesignBefore-and-after study.MethodsAll patients in Central Norway Health Region between 2007 and 2018 were included. They switched from therapy 2014 2017. The primary outcome was quiescence uveitis before after switch. All seen every 1-3 months. Visits binned into 3-month long periods each patient takingboth medications. Poisson regression analysis used estimate incidence rate ratio (IRR) 2 treatments.ResultsTwenty-nine treated with infliximab. Twenty-three those majority white (87%), female (92%), had anterior (65%). For taking drugs, median duration was38 months (range: 8-131 months) 15 5-55 months), respectively. Concomitant immunosuppressive medications topical oral steroids similarly during both IRR 0.91 (95% confidence intervals [CI]: 0.7-1.1; P = 0.38), which indicated no statistically significant differences achieving Also, there flare events switch (IRR: 1.04; 95% CI: 0.36-2.98; 0.95). adjusted intraocular surgery 0.90 0.37).ConclusionsNo evidence effectiveness found comparing uveitis. To Before-and-after study. treatments. Twenty-nine 0.37). No